Tasly

Cellatopia Secures Nearly CNY Ten Mn in Seed Funding

EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).

Haier Biomedical 'Smart Blood City Network' Lands in Brazil

Brazil, as the largest country and economy in South America, faces numerous challenges brought about by an aging population. With the country's economy continuing to grow, healthcare issues are receiving increasing attention, and the demand for medical services is rising year by year.

D3 Bio Completes A+ Round Financing, Accelerates Development of Product Pipeline

EqualOcean has learned that on April 8, 2024, D3 Bio(德昇济医药), a biotechnology company focused on the development and commercialization of innovative cancer and immune precision therapies, announced the successful completion of its A+ round financing led by Medicxi, a prominent European life sciences investment firm. The financing amounted to USD 62 million, with existing investor, Matrix Partners(经纬创投), also participating.

China-Indonesia Joint Venture Surgical String Plant in Indonesia

EqualOcean | Southern Weekly 2022 'China Greenwashing List'

Nine companies have been listed on China's Greenwashing List, drawing wider attention to the issue of greenwashing.

EqualOcean｜China's Top 20 ESG Performers Among Private Enterprises（Part III）

Private enterprises are actively embracing the transformative era

Pure Global: The International Engine of Medical Technology Globalization

As a pioneer in international regulatory management and clinical solutions, Pure Global has evolved into an indispensable partner for medical technology companies. Through its outstanding data technology, seasoned industry expert team, and transnational capabilities, Pure Global empowers its partners to achieve global growth. Presently, Pure Global's services span more than 25 countries and regions, offering tailored solutions for the entire lifecycle of medical devices.

Lanja has completed the Series A funding of hundred millions CNY

Shanghai Lanja Medical Technology Co., Ltd (“Lanja”) recently has announced the completion of the Series A funding of hundred millions CNY.

RabPharma has completed the Series A+ funding of hundred millions CNY

Zhongshan RabPharma Biopharmaceutical Co., Ltd. (“RabPharma”) recently has announced the completion of the Series A+ funding of hundred millions CNY.

Powertight has completed a pre-Series A funding of hundred millions CNY

Powertight Biotechnology (Hangzhou) Co., Ltd. (“Powertight”) recently has announced the completion of a pre-Series A funding of hundred millions CNY.

Foremed Legend has completed the pre-Series A+ funding

Suzhou Foremed Legend Medical Technology Company, Ltd. (“Foremed Legend”) recently has announced the completion of pre-Series A+ funding.

Surgical Robotics Company Rovono Surgical Nets Nearly 200 Mn in Pre-B+ Round

EqualOcean has learned that Rovono Surgical(Chinese: 瑞龙诺赋), a laparoscopic surgical robot developer, has completed a pre-B+ round of financing of nearly CNY 200 million.

Bioprofile completed a Series A funding of hundred millions CNY

Shanghai Bioprofile Technology Company, Ltd. (“Bioprofile”) recently has announced the completion of hundred millions of CNY in Series A funding.

CSH Medical completed a Series A+ funding of nearly one hundred million CNY

CSH Medical Equipment (Shanghai) Co., Ltd (“CSH Medical”) recently has announced the completion of nearly one hundred million CNY in Series A+ funding.

Mateside has completed the first round of financing

Zhejiang Mateside Medical Device Technology Co., Ltd. (“Mateside”) recently has announced the completion of the first round of nearly 100 million CNY financing.

High-end Medical Ceramics Manufacturer Arthrone Nets More than CNY 100 Mn in Series C

EqualOcean has learned that high-end medical ceramics manufacturer Arthrone(Chinese: 安颂科技) has recently completed a CNY 100 million Series C round of financing.

Milestone Biotech has completed a Series A funding of over a hundred million CNY

Milestone Biotechnologies Co., Ltd. (“Milestone Biotech”) recently has announced the completion of a Series B2 funding of over a hundred million CNY.

Bostal has completed a Series B2 funding of hundred millions CNY

Bostal Drug Delivery Co., Ltd. (“Bostal”) recently has announced the completion of a Series B2 funding of hundred millions CNY.

AI Pharmaceutical R&D Company DP Technology Raises New Round of Over CNY 700 Mn Financing

EqualOcean has learned that DP Technology（深势科技）, an AI pharmaceutical research company, has recently successfully completed a funding round of over CNY 700 million. Investors in this round include Zhongyuan Capital（众源资本）, MSA Capital（和玉资本）, Loyal Valley Capital（正心谷资本）, Evergreen Scitech Delta（深势科技）, and many other industry-specific investors, with Lighthouse Capital（光源资本） serving as the exclusive financial advisor.

Saints Sages has completed the Series B funding

Shanghai Saints Sages Surgical Co., Ltd. (“Saints Sages”) recently has announced the completion of the Series B funding, Qiming Venture Partners (启明创投) is the largest institutional investor.